Search

Your search keyword '"Patard, J. J."' showing total 464 results
Start Over Author "Patard, J. J."
464 results on '"Patard, J. J."'

70. A0992 - Machine learning approach to predict pT3a upstaging of clinically localized renal cell carcinoma and oncological outcomes after surgery (UroCCR 15 study)

Author

de Hauteclocque, A., Ferrer, L., Ambrosetti, D., Ricard, S., Bigot, P., Bensalah, K., Villers, A., Henon, F., Doumerc, N., Méjean, A., Verkarre, V., Dariane, C., Larré, S., Champy, C., De La Taille, A., Bruyère, F., Rouprêt, M., Paparel, P., Droupy, S., Fontenil, A., Patard, J-J., Boissier, R., Yacoub, M., Colin, T., and Bernhard, J-C.

Published
2022
Full Text
View/download PDF

73. Facteurs prédictifs et pronostics du cancer du rein à composante sarcomatoïde. Résultats d’une étude UCLA et UroCCR 45

Author

Lebâcle, C., primary, Pooli, A., additional, Faiena, I., additional, Johnson, D., additional, Bernhard, J.C., additional, Paparel, P., additional, Bensalah, K., additional, Beauval, J.B., additional, Méjean, A., additional, Dariane, C., additional, Bigot, P., additional, Lang, H., additional, Bessede, T., additional, De La Taille, A., additional, Salomon, L., additional, Rouprêt, M., additional, Leon, P., additional, Larré, S., additional, Cussenot, O., additional, Bruyère, F., additional, Long, J.-A., additional, Ouzaid, I., additional, Irani, J., additional, Patard, J.-J., additional, Chamie, K., additional, Drakaki, A., additional, and Pantuck, A.J., additional

Published
2018
Full Text
View/download PDF

75. Overall survival and oncological outcomes after partial nephrectomy and radical nephrectomy for cT2a renal tumors: A collaborative international study from the French kidney cancer research network UroCCR

Author

Reix, B., Bernhard, J.-C., Patard, J.-J., Bigot, P., Villers, A., Suer, E., Vuong, N. S., Verhoest, G., Alimi, Q., Beauval, J.-B., Benoit, T., Nouhaud, F.-X., Lenormand, C., Hamidi, N., Cai, J., Eto, M., Larre, S., El Bakhri, A., Ploussard, G., Hung, A., Koutlidis, N., Schneider, A., Carrouget, J., Droupy, S., Marchal, S., Doerfler, A., Seddik, S., Matsugasumi, T., Orsoni, X., Descazeaud, A., Pfister, C., Bensalah, K., Soulie, M., Gill, I., Flamand, V., CCAFU, Kidney Cancer, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'urologie, andrologie et transplantation rénale, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Institut de Génétique et Développement de Rennes (IGDR), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre d'Études Biologiques de Chizé - UMR 7372 (CEBC), Université de La Rochelle (ULR)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), CHU Pontchaillou [Rennes], Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'urologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Institut de recherches sur la catalyse et l'environnement de Lyon (IRCELYON), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Reims (CHU Reims), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Terres Inovia, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Université de Montpellier (UM), Service d'Urologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Chirurgie urologique et andrologie [CHU Limoges], CHU Limoges, CHU Toulouse [Toulouse], Université Lille Nord de France (COMUE), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Institut National de la Recherche Agronomique (INRA)-Université de La Rochelle (ULR)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Recherche Agronomique (INRA)-Université de La Rochelle (ULR), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Institut National de la Recherche Agronomique (INRA)-La Rochelle Université (ULR)-Centre National de la Recherche Scientifique (CNRS), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, medicine.medical_specialty, Biomedical Research, Urology, medicine.medical_treatment, [SDV]Life Sciences [q-bio], International Cooperation, 030232 urology & nephrology, Outcomes, Nephrectomy, Article, 03 medical and health sciences, Sparing surgery, Résultats oncologiques, 0302 clinical medicine, Renal cell carcinoma, medicine, Carcinoma, Partial nephrectomy, Humans, Stage (cooking), Survival rate, Néphrectomie partielle, Carcinoma, Renal Cell, Aged, Neoplasm Staging, Retrospective Studies, Cancer du rein, business.industry, Renal Cell, Retrospective cohort study, Middle Aged, medicine.disease, Kidney Neoplasms, 3. Good health, Survival Rate, Renal cancer, Treatment Outcome, Survie globale, Oncology, 030220 oncology & carcinogenesis, Propensity score matching, Female, France, business, Kidney cancer
Abstract

Summary Background Partial nephrectomy (PN) is recommended as first-line treatment for cT1 stage kidney tumors because of a better renal function and probably a better overall survival than radical nephrectomy (RN). For larger tumors, PN has a controversial position due to lack of evidence showing good cancer control. The aim of this study was to compare the results of PN and RN in cT2a stage on overall survival and oncological results. Method A retrospective international multicenter study was conducted in the frame of the French kidney cancer research network (UroCCR). We considered all patients aged ≥ 18 years who underwent surgical treatment for localized renal cell carcinoma (RCC) stage cT2a (7.1–10 cm) between 2000 and 2014. Cox and Fine-Gray models were performed to analyze overall survival (OS), cancer specific survival (CSS) and cancer-free survival (CFS). Comparison between PN and RN was realized after an adjustment by propensity score considering predefined confounding factors: age, sex, tumor size, pT stage of the TNM classification, histological type, ISUP grade, ASA score. Results A total of 267 patients were included. OS at 3 and 5 years was 93.6% and 78.7% after PN and 88.0% and 76.2% after RN, respectively. CSS at 3 and 5 years was 95.4% and 80.2% after PN and 91.0% and 85.0% after RN. No significant difference between groups was found after propensity score adjustment for OS (HR 0.87, 95% CI: 0.37–2.05, P = 0.75), CSS (HR 0.52, 95% CI: 0.18–1.54, P = 0.24) and CFS (HR 1.02, 95% CI: 0.50–2.09, P = 0.96). Conclusion PN seems equivalent to RN for OS, CSS and CFS in cT2a stage kidney tumors. The risk of recurrence is probably more related to prognostic factors than the surgical technique. The decision to perform a PN should depend on technical feasibility rather than tumor size, both to imperative and elective situation. Level of evidence 4.

Published
2017

76. Postoperative outcomes of elderly patients undergoing partial nephrectomy: A multicentric-study of the French research network on kidney cancer UroCCR

Author

Duc, S., primary, Bensalah, K., additional, Bigot, P., additional, Paparel, P., additional, Beauval, J.-B., additional, Salomon, L., additional, De La Taille, A., additional, Bessede, T., additional, Lang, H., additional, Nouhaud, F.X., additional, Baumert, H., additional, Roupret, M., additional, Long, J.A., additional, Villers, A., additional, Patard, J.-J., additional, Soulie, M., additional, Mejean, A., additional, Videau, M.-N., additional, and Bernhard, J.-C., additional

Published
2018
Full Text
View/download PDF

79. Adjuvant sunitinib (SU) in patients (pts) with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial

Author

Staehler, M., primary, Motzer, R.J., additional, George, D.J., additional, Pandha, H.S., additional, Donskov, F., additional, Escudier, B., additional, Kliment, J., additional, Pantuck, A.J., additional, Patel, A., additional, Deannuntis, L., additional, Bhattacharyya, H., additional, Lin, X., additional, Lechuga, M., additional, Serfass, L., additional, Patard, J-J., additional, and Ravaud, A., additional

Published
2017
Full Text
View/download PDF

80. S-TRAC adjuvant sunitinib phase 3 trial in patients with high risk renal cell carcinoma: Subgroups analyses by risk factors

Author

Staehler, M., primary, Patard, J.-J., additional, Pantuck, A., additional, Ravaud, A., additional, Motzer, R., additional, Pandha, H., additional, George, D., additional, Chang, Y.-H., additional, Escudier, B., additional, Donskov, F., additional, Magheli, A., additional, Carteni, G., additional, Laguerre, B., additional, Tomczak, P., additional, Breza, J., additional, Gerletti, P., additional, Lechuga, M., additional, Lin, X., additional, Casey, M., additional, and Patel, A., additional

Published
2017
Full Text
View/download PDF

81. Impact de l’assistance robotique sur la pratique et les résultats de la chirurgie rénale conservatrice : une expérience monocentrique

Author

Fardoun, T., Peyronnet, B., Oger, E., Verhoest, G., Mathieu, R., Khene, Z., Pradere, B., Alimi, Q., Manunta, A., Rioux-Leclercq, N., Patard, J.-J., Kammerer-Jacquet, S.-F., and Bensalah, K.

Abstract

L’objectif de ce travail était d’analyser l’évolution des pratiques et des résultats de la néphrectomie partielle (NP) avec l’acquisition du robot Da Vinci®.

Published
2024
Full Text
View/download PDF

83. genitourinary tumours, non prostate Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC)

Author

Ravaud, A., primary, Motzer, R.J., additional, Pandha, H.S., additional, Staehler, M., additional, George, D., additional, Pantuck, A.J., additional, Patel, A., additional, Chang, Y.-H., additional, Escudier, B., additional, Donskov, F., additional, Magheli, A., additional, Carteni, G., additional, Laguerre, B., additional, Tomczak, P., additional, Breza, J., additional, Gerletti, P., additional, Lin, X., additional, Lechuga, M., additional, Martini, J.-F., additional, and Patard, J.-J., additional

Published
2016
Full Text
View/download PDF

85. 405 Comparison of 1,800 robotic and open partial nephrectomies for renal tumors

Author

Peyronnet, B., primary, Vaessen, C., additional, Grassano, Y., additional, Benoit, T., additional, Carrouget, J., additional, Pradère, B., additional, Giwerc, A., additional, Beauval, J-B., additional, Seisen, T., additional, Nouhaud, F., additional, Bigot, P., additional, Doumerc, N., additional, Bernhard, J-C., additional, Mejean, A., additional, Patard, J-J., additional, Roupret, M., additional, and Bensalah, K., additional

Published
2016
Full Text
View/download PDF

86. 1092 Imperative indications of nephron sparing technique: Partial nephrectomy vs percutaneous ablative therapy

Author

Long, J-A., primary, Bernhard, J-C., additional, Bigot, P., additional, Paparel, P., additional, Boissier, R., additional, Rioux-Leclercq, N., additional, Albiges, L., additional, Bodin, T., additional, Nouhaud, F-X., additional, Gimel, P., additional, Mejean, A., additional, Roupret, M., additional, Masson-Lecomte, A., additional, Grenier, N., additional, Cornelis, F., additional, Grassano, Y., additional, Comat, V., additional, Le, Clerc Q.C., additional, Rigaud, J., additional, Salomon, L., additional, Rambeaud, J-J., additional, Sengel, C., additional, Verhoest, G., additional, Patard, J-J., additional, and Bensalah, K., additional

Published
2016
Full Text
View/download PDF

87. Ischemia is not an independent predictive factor of chronic renal failure after partial nephrectomy in a solitary kidney in patients without pre-operative renal insufficiency

Author

Bahi, R., Pignot, G., Hammoudi, Y., Bensalah, K., Oger, E., Laguna, P., Barwari, K., Bessede, T., Rigaud, J., Roupret, M., Bernhard, J. C., Long, J. A., Zisman, A., Berger, J., Paparel, P., Lechevallier, E., Bertini, R., Salomon, L., Bex, A., Farfara, R., Ljungberg, Börje, Rodriguez, A. R., Patard, J. J., Bahi, R., Pignot, G., Hammoudi, Y., Bensalah, K., Oger, E., Laguna, P., Barwari, K., Bessede, T., Rigaud, J., Roupret, M., Bernhard, J. C., Long, J. A., Zisman, A., Berger, J., Paparel, P., Lechevallier, E., Bertini, R., Salomon, L., Bex, A., Farfara, R., Ljungberg, Börje, Rodriguez, A. R., and Patard, J. J.

Abstract

Objective: To assess the influence of vascular clamping and ischemia time on long-term post-operative renal function following partial nephrectomy (PN) for cancer in a solitary kidney. Patients and methods: This is a retrospective study including 259 patients managed by PN between 1979 and 2010 in 13 centers. Clamping use, technique choice (pedicular or parenchymal clamping), ischemia time, and peri-operative data were collected. Pre-operative and last follow-up glomerular filtration rates were compared. A multivariate analysis using a Cox model was performed to assess the impact of ischemia on post-operative chronic renal failure risk. Results: Mean tumor size was 4.0 ± 2.3 cm and mean pre-operative glomerular filtration rate was 60.8 ± 18.9 mL/min. One hundred and six patients were managed with warm ischemia (40.9%) and 53 patients with cold ischemia (20.5%). Thirty patients (11.6%) have had a chronic kidney disease. In multivariate analysis, neither vascular clamping (P = 0.44) nor warm ischemia time (P = 0.1) were associated with a pejorative evolution of renal function. Pre-operative glomerular filtration rate (P < 0.0001) and blood loss volume (P = 0.02) were significant independent predictive factors of long-term renal failure. Conclusion: Renal function following PN in a solitary kidney seems to depend on non-reversible factors such as pre-operative glomerular filtration rate. Our findings minimize the role of vascular clamping and ischemia time, which were not significantly associated with chronic renal failure risk in our study.

Published
2015
Full Text
View/download PDF

88. An Antigen Recognized by Autologous CTLs on a Human Bladder Carcinoma

Author

Guéguen, M., Patard, J. -J, Gaugler, B., Brasseur, F., Jean-Christophe Renauld, Cangh, P. J., Boon, T., and Den Eynde, B. J.

Subjects
Immunology, Immunology and Allergy
Abstract

By stimulating blood lymphocytes with autologous bladder carcinoma cells that had been transfected with B7-1, we obtained a panel of CTL clones which lyse specifically the bladder tumor cells in an MHC class I-restricted fashion. Based on inhibition with anti-HLA Abs and the recognition of allogeneic tumor cells, we could distribute our clones in three groups that recognized three distinct Ags. We characterized one of these Ags by screening a cDNA library prepared with the RNA from this bladder tumor line. This new tumor Ag is a peptide presented by HLA-B4403 molecules. It is produced by a point mutation in a gene that is recorded in databases under the name KIAA0205, is ubiquitously expressed, and whose function is unknown. We also found this mutation in the tumor sample that was originally resected from this patient, but the mutation was not found in the 100 or more independent tumors of various histologic types that were tested. This report is the first to describe the isolation of CTL clones directed against human bladder cancer and the molecular characterization of a bladder tumor Ag.

Published
1998

90. [CCAFU Recommendations 2013: Renal cancer]

Author

Patard, J.-J., Baumert, H., Bensalah, K., Bernhard, J.-C., Bigot, P., Escudier, B., Grenier, N., Hétet, J.-F., Long, J.-A., Méjean, A., Paparel, P., Richard, S., Rioux-Leclercq, N., Coloby, P., Soulié, M., CCAFU, Les, Service d'urologie, andrologie et transplantation rénale, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Imagerie moléculaire et fonctionnelle: de la physiologie à la thérapie, Université Bordeaux Segalen - Bordeaux 2-IFR8-Centre National de la Recherche Scientifique (CNRS), Laboratoire de recherche en Hydrodynamique, Énergétique et Environnement Atmosphérique (LHEEA), École Centrale de Nantes (ECN)-Centre National de la Recherche Scientifique (CNRS), Service d'urologie, CHU Grenoble-Hôpital Michallon, Applications des ultrasons à la thérapie, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie cardiovasculaire, Université Montpellier 1 (UM1)-IFR3, Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'anatomie et cytologie pathologiques [Rennes] = Anatomy and Cytopathology [Rennes], CHU Pontchaillou [Rennes], Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service d'Urologie - Transplantation Rénale - Andrologie, CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Département d'Urologie-Andrologie et Transplantation Rénale [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)

Subjects
[SDV]Life Sciences [q-bio], Decision Trees, Humans, urologic and male genital diseases, Carcinoma, Renal Cell, Kidney Neoplasms
Abstract

International audience; INTRODUCTION: The renal sub Committee of the CCAFU established guidelines for diagnosis, treatment, evaluation and standard of care for renal cell carcinoma. METHODS: 2010 Guidelines were updated based on systematic literature search performed by the sub-Committee in Medline and PubMed databases to evaluate references, levels of evidence and grade of recommendation. RESULTS: Multiphasic CT is the standard imaging technique for renal tumors diagnosis. Percutaneous renal biopsies are increasingly important for the management of localized RCC. Partial Nephrectomy is the first option when technically feasible for cT1 tumours. Open surgery remains the standard approach for locally advanced RCCs. New drugs are available for the treatment of metastatic RCC while the role of nephrectomy needs to be established by the Carmena trial. CONCLUSIONS: Conservative and mini-invasive therapies are increasingly important for the management of localized RCC. Therapeutic armamentarium continues to increase in mRCC.

Published
2013

91. RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs

Author

Beuselinck, B, primary, Jean-Baptiste, J, additional, Couchy, G, additional, Job, S, additional, De Reynies, A, additional, Wolter, P, additional, Théodore, C, additional, Gravis, G, additional, Rousseau, B, additional, Albiges, L, additional, Joniau, S, additional, Verkarre, V, additional, Lerut, E, additional, Patard, J J, additional, Schöffski, P, additional, Méjean, A, additional, Elaidi, R, additional, Oudard, S, additional, and Zucman-Rossi, J, additional

Published
2015
Full Text
View/download PDF

93. 915 Is laparoscopic partial nephrectomy a safe treatment option for unexpected pT3a renal cell carcinoma?

Author

Bernhard, J-C., primary, Patard, J-J., additional, Bigot, P., additional, Suer, E., additional, Vuong, N.S., additional, Verhoest, G., additional, Alimi, Q., additional, Flamand, V., additional, Reix, B., additional, Beauval, J-B., additional, Benoit, T., additional, Nouhaud, F-X, additional, Lenormand, C., additional, Hamidi, N., additional, Hung, A., additional, Cai, J., additional, Eto, M., additional, Larre, S., additional, El Bakri, A., additional, Baco, E., additional, Ploussard, G., additional, Koutlidis, N., additional, Schneider, A., additional, Roupret, M., additional, Leon, P., additional, Carrouget, J., additional, Droupy, S., additional, Marchal, S., additional, Doerfler, A., additional, Sofiane, S., additional, Matsugasumi, T., additional, Orsoni, X., additional, Descazeaud, A., additional, Pfister, C., additional, Bensalah, K., additional, Méjean, A., additional, Soulie, M., additional, and Gill, I., additional

Published
2015
Full Text
View/download PDF

95. 727 From clinically localized to pT3a renal cell carcinoma: What are the predictive factors of unexpected pathologic upstaging?

Author

Bernhard, J-C., primary, Patard, J-J., additional, Bigot, P., additional, Suer, E., additional, Vuong, N.S., additional, Verhoest, G., additional, Alimi, Q., additional, Flamand, V., additional, Reix, B., additional, Beauval, J-B., additional, Benoit, T., additional, Nouhaud, F-X., additional, Lenormand, C., additional, Hamidi, N., additional, Hung, A., additional, Cai, J., additional, Eto, M., additional, Larre, S., additional, El Bakri, A., additional, Baco, E., additional, Ploussard, G., additional, Koutlidis, N., additional, Schneider, A., additional, Roupret, M., additional, Leon, P., additional, Carrouget, J., additional, Droupy, S., additional, Marchal, S., additional, Doerfler, A., additional, Seddik, S., additional, Matsugasumi, T., additional, Orsoni, X., additional, Descazeaud, A., additional, Pfister, C., additional, Bensalah, K., additional, Méjean, A., additional, Soulie, M., additional, and Gill, I., additional

Published
2015
Full Text
View/download PDF

96. L’ischémie a un impact limité sur la fonction rénale après néphrectomie partielle sur rein unique chez les patients sans insuffisance rénale préopératoire

Author

Bahi, R., primary, Pignot, G., additional, Hammoudi, Y., additional, Bensalah, K., additional, Oger, E., additional, Laguna, P., additional, Barwari, K., additional, Bessède, T., additional, Rigaud, J., additional, Roupret, M., additional, Bernhard, J.-C., additional, Long, J.-A., additional, Zisman, A., additional, Berger, J., additional, Paparel, P., additional, Lechevallier, E., additional, Bertini, R., additional, Salomon, L., additional, Bex, A., additional, Farfara, R., additional, Ljungberg, B., additional, Rodriguez, A.R., additional, and Patard, J.-J., additional

Published
2015
Full Text
View/download PDF

97. Positive Surgical Margin Appears to Have Negligible Impact on Survival of Renal Cell Carcinomas Treated by Nephron-Sparing Surgery

Author

Bensalah, K. Pantuck, A.J. Rioux-Leclercq, N. Thuret, R. Montorsi, F. Karakiewicz, P.I. Mottet, N. Zini, L. Bertini, R. Salomon, L. Villers, A. Soulie, M. Bellec, L. Rischmann, P. De La Taille, A. Avakian, R. Crepel, M. Ferriere, J.-M. Bernhard, J.-C. Dujardin, T. Pouliot, F. Rigaud, J. Pfister, C. Albouy, B. Guy, L. Joniau, S. van Poppel, H. Lebret, T. Culty, T. Saint, F. Zisman, A. Raz, O. Lang, H. Spie, R. Wille, A. Roigas, J. Aguilera, A. Rambeaud, B. Piñeiro, L.M. Nativ, O. Farfara, R. Richard, F. Roupret, M. Doehn, C. Bastian, P.J. Muller, S.C. Tostain, J. Belldegrun, A.S. Patard, J.-J.

Abstract

Background: The occurrence of positive surgical margins (PSMs) after partial nephrectomy (PN) is rare, and little is known about their natural history. Objective: To identify predictive factors of cancer recurrence and related death in patients having a PSM following PN. Design, setting, and participants: Some 111 patients with a PSM were identified from a multicentre retrospective survey and were compared with 664 negative surgical margin (NSM) patients. A second cohort of NSM patients was created by matching NSM to PSM for indication, tumour size, and tumour grade. Measurements: PSM and NSM patients were compared using student t tests and chi-square tests on independent samples. A Cox proportional hazards regression model was used to test the independent effects of clinical and pathologic variables on survival. Results and limitations: Mean age at diagnosis was 61 ± 12.5 yr. Mean tumour size was 3.5 ± 2 cm. Imperative indications accounted for 39% (43 of 111) of the cases. Some 18 patients (16%) underwent a second surgery (partial or total nephrectomy). With a mean follow-up of 37 mo, 11 patients (10%) had recurrences and 12 patients (11%) died, including 6 patients (5.4%) who died of cancer progression. Some 91% (10 of 11) of the patients who had recurrences and 83% of the patients (10 of 12) who died belonged to the group with imperative surgical indications. Rates of recurrence-free survival, of cancer-specific survival, and of overall survival were the same among NSM patients and PSM patients. The multivariable Cox model showed that the two variables that could predict recurrence were the indication (p = 0.017) and tumour location (p = 0.02). No other variable, including PSM status, had any effect on recurrence. None of the studied parameters had any effect on the rate of cancer-specific survival. Conclusions: PSM status occurs more frequently in cases in which surgery is imperative and is associated with an increased risk of recurrence, but PSM status does not appear to influence cancer-specific survival. Additional follow-up is needed. © 2009 European Association of Urology.

Published
2010

98. Independent predictors of contralateral metachronous upper urinary tract transitional cell carcinoma after nephroureterectomy: Multi-institutional dataset from three European centers: Original Article: Clinical Investigation

Author

Novara, G., Marco, V. D., Dalpiaz, O., Galfano, A., Bouygues, V., Gardiman, M., Martignoni, Guido, Patard, J. J., Artibani, Walter, and Ficarra, V.

Subjects
bladder carcinoma, cancer patient, recurrent disease, probability, retrospective study, reimplantation, Upper urinary tract transitional cell carcinoma, Kidney, Nephroureterectomy, Nephrectomy, endoscopic surgery, male, Recurrence, cancer diagnosis, transitional cell carcinoma, follow up, Humans, human, multimodality cancer therapy, BCG vaccine, nephrostomy, Retrospective Studies, urinary tract carcinoma, Ureteral Neoplasms, Ureterectomy, adult, Bladder cancer, Carcinoma, article, cancer center, clinical trial, Middle Aged, cohort analysis, Prognosis, major clinical study, Kidney Neoplasms, Europe, aged, female, multicenter study, urologic surgery, cancer surgery, cancer therapy, diagnostic accuracy, histopathology, priority journal, Transitional Cell, Ureter
Published
2009

Catalog

Books, media, physical & digital resources
See catalog results